Although DAA medications have demonstrated excellent safety and efficacy in non-pregnant individuals, they are not currently approved for HCV treatment in pregnant women due to a lack of safety data. Clinical trials assessing the safety of DAAs in pregnancy and real-world studies regarding the ou…
The 2-day meeting in Chicago on 8-9 July 2022 convened 129 consensus survey participants in person or online. The participants originated from 32 countries, representing multiple societies including AASLD, EASL, APASL, ALEH, AGA and UEG, patients and patient advocacy organizations, regulators and…
28 July 2022 Channel 4 News from London: Liver disease deaths in the UK have soared by 400% since 1970 with an average of 40 deaths per day. We know that liver transplantation remains a radical, expensive and risky option, while 90% of liver disease is in fact preventable. EASL’s Prof. Emmanuel …
28 July 2022 This World Hepatitis Day, EASL revoices commitment to working towards the elimination of viral hepatitis and striving towards the World Health Organization’s goal of a hepatitis-free world by 2030. To mark this important day, we are launching the EASL Policy Dialogues video series, p…
Prof. Vinay Sundaram, Associate Professor of Medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center, passed away on July 14, 2022. Prof. Sundaram was one of the leading researchers in the field of acute-on-chronic liver failure and was actively involved in studies ai…
EASL has launched several highly influential Clinical Practice Guidelines (CPGs). The objective of these CPGs is to provide simple, clear, and evidence-based guidelines that can be used for patient management and reimbursement policies all over Europe. EASL CPGs have become a global reference, pr…
7 July 2022 At ILC 2022, we released our Annual Report 2021 to the community. Discover how we turned stumbling blocks into steppingstones through 2021: running onsite and online events with creativity and innovation, boosting our educational and digital offerings, running schools to boost skills,…
ClarivateTM Analytics released the 2022 update of its Journal Citation Reports©, including the much anticipated 2021 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2021 impact factor of 30.083, up from the 2020 score of 25.083. Gen…
28 June 2022 It is with great pleasure that EASL announces that their first open-access journal JHEP Reports has received its first impact factor ever of 9.917. This milestone event has taken place only three years after the publication of its first issue in May 2019, and the journal being accep…
The European Association for the Study of the Liver (EASL) has improved the way you will connect to all our EASL applications with a new Single Sign On solution. One username, one password for all our applications.…
